Table 2 from First-in-Human Phase I/IIa Study of the First-in-Class CDK2/4/6 Inhibitor PF-06873600 Alone or with Endocrine Therapy in Patients with Breast Cancer

Key Points

• MAIN FINDING: The study evaluates the safety of the CDK2/4/6 inhibitor PF-06873600 in combination with endocrine therapy.
• KEY EVIDENCE: Over 15% of patients experienced treatment-emergent adverse events (TEAEs), with safety data collected from 151 participants.
• APPROACH: The trial followed a Phase I/IIa design to assess the effects on patients with breast cancer receiving the treatment.
• SIGNIFICANCE: Results suggest potential benefits and risks of combining CDK inhibitors with endocrine therapy for breast cancer treatment.